SCHEMBL5057322

SCHEMBL5057322

Cc1csc(CNC(=O)c2ccc3c(c2)N=C(Cl)c2ccccc2S3)c1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.54
TP53 P04637 4/20 0.53
POLB P06746 1/20 0.53
PKM P14618 2/20 0.53
ALDH1A1 P00352 2/20 0.53
CNR1 P21554 7/20 0.52
PLA2G1B P04054 4/20 0.52
ATG4B Q9Y4P1 2/20 0.52
CNR2 P34972 2/20 0.52
HTT P42858 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14043738 0.89 LMNA (0.42) LMNATP53POLBPKMALDH1A1
SCHEMBL5064836 0.86 CNR1 (0.73) LMNATP53POLBPKMALDH1A1
SCHEMBL5062748 0.86 CNR1 (0.67) LMNATP53POLBPKMALDH1A1
SCHEMBL5058704 0.84 CNR1 (0.58) LMNATP53POLBPKMALDH1A1
SCHEMBL5054084 0.84 CNR1 (0.53) LMNATP53POLBPKMALDH1A1
SCHEMBL5064738 0.84 CNR1 (0.49) LMNATP53POLBPKMALDH1A1
SCHEMBL5057611 0.83 CNR1 (0.53) LMNATP53POLBPKMALDH1A1
SCHEMBL5057739 0.83 LMNA (0.58) LMNATP53POLBPKMALDH1A1
SCHEMBL5064837 0.83 POLB (0.71) LMNATP53POLBPKMALDH1A1
SCHEMBL5057296 0.82 CNR1 (0.72) LMNATP53POLBPKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 US disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 US disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE CNR1, CNR2, FAAH LMNA 3921/4885TP53 4870/4885POLB 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.